KOREA WHO
-
-
-
CEO of ImmuneOncia Therapeutics
Kim Heung-tae
From Renowned Oncologist to Entrepreneur Driving Korea’s First Immunotherapy
-
Last Updated on Oct 31, 2025
-
CEO of ImmuneOncia Therapeutics
Life Summary
Kim Heung-tae is the CEO of ImmuneOncia.
He aims to develop Korea’s first domestically produced immuno-oncology drug and change the standard of cancer treatment.
He was born on March 6, 1956, in Seoul.
He graduated from Seoul National University with a degree in medicine and earned both his master’s and doctoral degrees in medicine from the same university’s graduate school.
He served as a research fellow in the Department of Hematology and Oncology at Seoul National University Hospital and as a special researcher at the affiliated Cancer Research Institute.
He was appointed as an associate professor in the Department of Hematology and Oncology at Dankook University College of Medicine and worked as a visiting researcher at the U.S. National Cancer Institute.
He held several key positions, including Head of Hematology and Oncology at the Korea Institute of Radiological & Medical Sciences, Director of the Lung Cancer Center and Clinical Trial Center at the National Cancer Center Hospital, Deputy Director of the hospital, Director of Planning and Coordination, and Head of the National Cancer Control Planning Division.
In 2021, he was appointed CEO of the biotech venture ImmuneOncia.
He transformed the company into a dynamic organization operating as “one team.”
He has successfully transitioned from a renowned oncologist to a professional executive at ImmuneOncia, a subsidiary of Yuhan Corporation.
#ImmuneOncia #KimHeungtae #Yuhan #immunotherapy #oncology #cancerresearch #biotech #Kbio #pharmaceuticals #leadership
He aims to develop Korea’s first domestically produced immuno-oncology drug and change the standard of cancer treatment.
He was born on March 6, 1956, in Seoul.
He graduated from Seoul National University with a degree in medicine and earned both his master’s and doctoral degrees in medicine from the same university’s graduate school.
He served as a research fellow in the Department of Hematology and Oncology at Seoul National University Hospital and as a special researcher at the affiliated Cancer Research Institute.
He was appointed as an associate professor in the Department of Hematology and Oncology at Dankook University College of Medicine and worked as a visiting researcher at the U.S. National Cancer Institute.
He held several key positions, including Head of Hematology and Oncology at the Korea Institute of Radiological & Medical Sciences, Director of the Lung Cancer Center and Clinical Trial Center at the National Cancer Center Hospital, Deputy Director of the hospital, Director of Planning and Coordination, and Head of the National Cancer Control Planning Division.
In 2021, he was appointed CEO of the biotech venture ImmuneOncia.
He transformed the company into a dynamic organization operating as “one team.”
He has successfully transitioned from a renowned oncologist to a professional executive at ImmuneOncia, a subsidiary of Yuhan Corporation.
#ImmuneOncia #KimHeungtae #Yuhan #immunotherapy #oncology #cancerresearch #biotech #Kbio #pharmaceuticals #leadership